• Treatment of Dysmenorrhea and Premenstrual Syndrome in Outpatient Settings – Modern Features 
To content

Treatment of Dysmenorrhea and Premenstrual Syndrome in Outpatient Settings – Modern Features 

HEALTH OF WOMAN.2015.6(102):36–41 

Treatment of Dysmenorrhea and Premenstrual Syndrome in Outpatient Settings – Modern Features 

O.V. Kachalina

Nizhny Novgorod state medical Academy 

The article discusses factors of formation and modern methods of treatment for dysmenorrhea and premenstrual syndrome. Conservative treatment includes combined hormonal contraceptives, physiotherapy, vitamin therapy and symptomatic therapy. Authors note the role of Dexalgin® and Nimesil® as the first-line therapy, along with combined hormonal contraception, in the treatment of primary dysmenorrhea and symptomatic treatment of premenstrual syndrome. The use of these drugs is characterized by a rapid onset of action, pronounced analgesic effect and well tolerability. 

Key words: dysmenorrhea, premenstrual syndrome, Dexalgin®, Nimesil®. 


1. Делироглу Э, Арвантинос ДИ. 1996. Некоторые подходы к изучению и лечению дисменореи. Вестн. Рос. ассоц. акуш. и гин. 4:50–2.

2. Стругацкий ВМ., Маланова ТБ, Аросланян КН. 2005. Физиотерапия в практике акушера-гинеколога: Клинические аспекты и рецептура. Медпресс.

3. Клинические рекомендации. Акушерство и гинекология. Под ред. Савельевой ГМ, Серова ВН, Сухих ГТ. 2009.

4. Мозес ВГ, Ожогина ЕВ. 2012. Первичная дисменорея, пособие для врачей.

5. Медицинские критерии приемлемости для использования методов лечения ВОЗ. 2004.

6. Воробьева ОВ. 2010. Взаимосвязь спектра безопасности нимесулида и особенностей его механизма действия, химической структуры и фармакокинетики. Consilium Medicum 2:5–8.

7. Инструкции по медицинскому применению препаратов, Видаль. 2010.

8. Инструкции по медицинскому применению препаратов Нимесил и Дексалгин.

9. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. 2002. Acceptance of altering the standart 21 day/7 day oral contraceptive ragimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynicol. 186;1142–9.

10. Akerlund M, Forsling M, Kindahl H. 1992. Stimulator of vasopressin release in women with primary dysmenorrhea and after oral contraceptive tritment. Br J Obstet Gynicol. 99: 680–4.

11. Yusoff Dawood M. 2006. Primari Dismenorrhea. Advances in Pathogenesis and Management. ACOG. 108:2.

12. Wiegratz I, Kuhl H. 2004. Прием оральных контрацептивов в режиме длинного цикла. Drugs 64:2447–2462.

13. Ulmsten U. 1985. Uterine activity and blood flow in normal and dysme-norrheic women. Baltimore (MD). Urban and Schwarzenberg. 103–124.

14. Dequeker J, Hawkey C., Kahan A et al. 1998. Improvement in gastrointestinal tolerabilitiof the selective cyclooxygenase inhibitors, meloxicam, compared with peroxicam; results of the safety and efficacy largescale evaluation of COX-ihibiting therapies thrial in osteoarthritis. Br.J.Rheu-matol. 37:946–51. http://dx.doi.org/10.1093/rheumatology/37.9.946

15. Herel Z. 2002. A contemporary approach to dysmenorrhea in adolescents. Paediatr drugs 4:797–805. http://dx.doi.org/10.2165/00128072-200204120-00004

16. Rainsford KD. 1996. Mode of action, uses and side-effects of anti-rheumatic drugs. In: Rainsford KD, ed. Advances in anti-rheumatic therapy. Boca Raton, FL: CRC Press: 59–111.

17. Davis R, Brogden RN. 1994. Nimesulide. An update of its pharmaco-dynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 48: 431–54.

18. Мультицентровое исследование методом «случайный контроль», 1999–2001 гг., 4309 пациентов. Адаптировано из Laporte JR et al. Drug Safety. 2004. 27(6):411–420.

19. Межевитинова ЕА. 1998. Контрацепция и здоровье женщины. Гинекология 2:29-39.

20. Banikarim C, Chaco MR, Kelder SH. 2000. Prevalence and impact of dysmenorrhea on Hispanic female adolescents. Arch Pediatr Adolesc Med. 154:1226–9. http://dx.doi.org/10.1001/archpedi.154.12.1226; PMid:11115307

21. Strinic T, Bukovic D, Pavelic L, Fajdic J, Herman I, Stipic I. et al. 2003. Anthropological and clinic characteristic in adolescent women with dys-menorrhea. Coll Antropol. 27:707–11.

22. French L. 2005. Dysmenorrhea. American Family Physician 71:2.

23. Altunyurt S, Gol M, Altunyurt S, Sezer O, Demir N. 2005 Primary dysmenorrhea and uterine blood flow: a color Doppler study. J Reprod Med. 50:251–5.

24. Lopez LM, Grimpes DA, Gallo MF, Schulz KF. 2010. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews 3. Art No.:CD003552.

25. Dawood MY. 1981. Hormones, prostaglandin and dysmenorrhea. In: Dawood MY, editor. Dysmenorrhea. Baltimore (MD); Williams and Wil-kens: 20–52.

26. Proctor ML, Roperts H, Farquar CM. 2001. Combinated oral contraceptive pill as treatment for primary dysmenorrhea. Cochrane Database of Systematic Reviews 3:CD002120.

27. Taha AS, Anderson VJ, Prasad R et al. 2007. Upper gastrointestinal bleeding and the changing use of COX-2 nonsteriodal anti-inflammatory drugs and low-dose aspirin. Aliment Pharmacol Ther. 26:1171–8. http://dx.doi.org/10.1111/j.1365-2036.2007.03458.x; PMid:17894659

28. Gislason GH, Rasmussen JN, Abildstorm SZ. 2009. Increased Mortality and cardiovascular Mortality Associated With Use of nonsteroidal Anti-inflammatory Drugs in Chronic Heart Failure. Arch intern med. 169(2):141–9.

29. Gich I et al. 1995. (6th Interscience World Conference on Inflammation, Antitheumatics, Analgetics and Immunomodulatiors. Geneva. 1995, March 28–30.

30. Metscher B. 2000. Fortschr Med. 118:147–151.

31. Zippel, Clin Drug Invest. 2006. 26(9):517–528.

32. Laporte JR et al. 2004. Drug Safety 27(6):411–420.

33. Lopez-Munoz FJ et al. 1998. J Clin Pharmacol. 38;12:11S–21S.

34. Carabaza A et al. 1997. Chirality 9:281–285.

35. Peat S. 2002. 10th World Congress on Pain. San Diego: 945–P215.

36. Laporte JR et al. 2004. Мультицентровое исследование методом «случайный контроль», 1999–2001 гг., 4309 пациентов. Drug Safety 27(6):411–420. http://dx.doi.org/10.2165/00002018-200427060-00005; PMid:15144234

37. Аlessandrini А, Ballarin Е, Ваstianon А, Мigliаvасса С. 1986. Clin Ther. 118(3):177–82.

38. Transdermal glyceril trinitrate in the management of primary dys-menorrhea. Int J Ginaecol Obstet. 69:113–8. 2000.

39. Ulmsten U. 1985. Calcium Dlocade as a rapid pharmacological to evaluate primary dysmenorrhea Ginaecol Obstet Invest. 20:78–83.

40. Gokhale LB. 1996. Curative treatment of primary dysmenorrhea. Indian jornal of medical Research 103:227–231.

41. Ziaei S, Zakeri M, Kazemnejad A. 2005. A randomized controlled trial of vitamin E in the treatment of primary dysmenorrhea. BJOG 112:466–9. http://dx.doi.org/10.1111/j.1471-0528.2004.00495.x; PMid:15777446

42. Proctor ML, Smith CA. 2002. Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhea. In: The Cochrane Lib-rari, 1. Oxford: update Software.

43. Halbreich U, Borenstein J, Pearlstein T et al. 2003. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocri-nology 28;3:1–23. http://dx.doi.org/10.1016/S0306-4530(03)00098-2http://dx.doi.org/10.1016/S0306-4530(02)00124-5

44. Wittchen HU, Becker E, Lieb R et al. 2002. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med. 32(1):119–32. http://dx.doi.org/10.1017/S0033291701004925

45. Angst J, Sellaro R, Merikan-gas KR et al. 2001. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand. 104(2):110–6.

46. Freeman EW, Sondheimer SJ. 2003. Premenstrual dysphoric disorder: recognition and treatment. Primary Care Companion J Clin Psychiatry 5:30–9. http://dx.doi.org/10.4088/PCC.v05n0106